Welcome to our dedicated page for Inotiv SEC filings (Ticker: NOTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inotiv, Inc. (NASDAQ: NOTV) SEC filings page on Stock Titan provides centralized access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-assisted summaries to help interpret key points. Inotiv is a contract research organization offering nonclinical and analytical drug discovery and development services and research models and related products and services, and its filings offer detailed insight into how this business operates and evolves.
Through periodic and current reports, investors can review how Inotiv reports performance in its Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments, including revenue drivers such as safety assessment services, general toxicology, biotherapeutic analysis, discovery and translational sciences services, and non-human primate product and service revenues. Annual and quarterly reports (such as Forms 10-K and 10-Q, when available) typically include segment discussions, risk factors, liquidity and capital resources, and descriptions of non-GAAP measures like Adjusted EBITDA that the company uses to evaluate its operations.
Current reports on Form 8-K, several of which are reflected in the recent data, highlight material events such as preliminary financial results, corrections to earnings releases, cybersecurity incidents, and legal and regulatory developments. Examples include disclosures about a cybersecurity incident affecting certain systems and data, proposed settlements of securities class action and derivative litigation, updates on investigations related to non-human primate importations, and engagement of financial advisors to explore potential debt refinancing alternatives.
Stock Titan’s interface is designed to surface these filings in real time as they are posted to EDGAR, while AI-generated explanations can help clarify complex sections, such as litigation descriptions, settlement terms, governance commitments, and capital structure updates. Users can also review insider and executive-related filings, such as Forms 3, 4, and 5 when available, to understand equity transactions by officers and directors.
By using the NOTV SEC filings page, investors and researchers can quickly locate Inotiv’s official regulatory communications and rely on AI tools to interpret how reported financial results, risk disclosures, legal matters, and strategic initiatives relate to the company’s nonclinical and research model-focused business.
Inotiv, Inc. reports that its lenders have granted a waiver of the minimum liquidity covenant in its Credit Agreement for the March 20, 2026 and March 27, 2026 liquidity test dates. The waiver applies only to that covenant for those two dates, and all other terms of the Credit Agreement remain unchanged.
Inotiv, Inc. reports that its lenders granted a waiver of the minimum liquidity covenant in its Credit Agreement for the March 6, 2026 and March 13, 2026 liquidity test dates. The waiver applies only to this specific covenant on those dates, and no other Credit Agreement terms were amended.
This temporary waiver means lenders agreed not to enforce the usual minimum liquidity requirement on those test dates, providing short-term flexibility while keeping the broader financing arrangement in place.
Inotiv, Inc.’s Chief Financial Officer Beth A. Taylor reported an automatic share sale related to tax withholding. On the transaction date, 2,888 shares of common stock were sold at an average price of $0.2929 per share to satisfy tax obligations upon vesting of restricted stock units.
The sale was executed by the company under a pre-arranged Rule 10b5-1 instruction entered into during the period from September 11, 2024 to October 9, 2024. After this transaction, Taylor’s directly held stake stands at 145,480 common shares.
Inotiv, Inc. Chief Strategy Officer John E. Sagartz reported an automatic sale of company stock to cover taxes on vested restricted stock units. On this transaction date, 2,119 shares of common stock were sold at an average price of $0.2908 per share under a pre-set Rule 10b5-1 instruction. Following this tax-withholding sale, Sagartz directly held 735,697 shares of Inotiv common stock.
Inotiv, Inc. President and CEO Robert Jr. Leasure reported an automatic sale of 16,810 shares of common stock on February 17, 2026. The shares were sold by the company on his behalf to cover tax withholding when restricted stock units vested, under a Rule 10b5-1 instruction entered between September 11 and October 9, 2024.
The weighted average sale price was about $0.2953 per share, with individual trades between $0.29 and $0.30. After this transaction, he directly holds 1,256,215 common shares. An additional 105,000 shares are held by an entity in which he is the majority security holder, and he disclaims ownership except for his economic interest.
Inotiv Inc. insider filing outlines planned stock sales under Rule 144. The notice covers up to 20,000 shares of common stock to be sold through Raymond James & Associates on or about February 17, 2026 on the NASDAQ, with an aggregate market value of $5,800 and total shares outstanding of 34,390,000.
The seller previously acquired 55,000 common shares on February 16, 2026 via an RSU grant from the issuer, with cash payment dated February 17, 2026. During the prior three months, the filer, Robert Leasure, sold 113,297 common shares on February 6, 2026 for gross proceeds of $56,216.
Inotiv, Inc. reported quarterly revenue of $120.9M for the three months ended December 31, 2025, roughly flat year over year, but posted an operating loss of $16.3M and a net loss of $28.4M or $0.83 per share. Cash and cash equivalents fell to $12.7M from $21.7M at September 30, 2025, while net cash used in operating activities was $5.4M.
Total assets were $734.3M against total liabilities of $625.3M, including $413.6M of debt, all classified as current because of covenant risk and maturities within 12 months. Management discloses substantial doubt about the company’s ability to continue as a going concern due to expected covenant noncompliance and upcoming term loan, revolver, convertible note and second-lien note maturities, and is pursuing cost controls and potential refinancing with no assurance of success.
Inotiv, Inc. reported first quarter fiscal 2026 results showing nearly flat revenue but continued losses. Revenue for the three months ended December 31, 2025 was $120.9 million, up 0.8% from $119.9 million a year earlier. Discovery & Safety Assessment revenue grew 12.0% to $48.0 million, while Research Models & Services revenue declined 5.4% to $72.9 million, mainly from lower non-human primate volumes.
Operating loss increased to $16.3 million from $15.5 million, and consolidated net loss widened slightly to $28.4 million. Adjusted EBITDA was $1.8 million, or 1.5% of revenue, compared with $2.6 million, or 2.2%, in the prior-year quarter. Cash and cash equivalents declined to $12.7 million at December 31, 2025 from $21.7 million at September 30, 2025, while total debt was $405.8 million. For the DSA services business, the book-to-bill ratio was 1.16x and backlog rose to $145.4 million, indicating growing contracted work despite current losses.
Inotiv President and CEO Robert Leasure Jr. had 113,297 shares of common stock automatically sold on February 2, 2026 at a weighted average price of $0.5034 per share to satisfy tax withholding obligations on vested restricted stock units.
Following this sell-to-cover transaction, he directly beneficially owned 1,273,025 common shares. An additional 105,000 shares are held by an entity for which he is the majority security holder, and he disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.
A holder of NOTV common stock has filed a notice of proposed sale under Rule 144. The filer plans to sell 120,000 shares through Raymond James & Associates on or about 02/02/2026 on the NASDAQ market, with an aggregate market value of $59,088.00. The issuer had 34,400,000 shares outstanding. The securities to be sold are part of a 300,000-share RSU grant of common stock acquired on 02/01/2026, with cash payment dated 02/02/2026.